18 April 2019

Jakko van Ingen received the ESCMID Young Investigator Award for his groundbreaking work on nontuberculous mycobacterial disease.

During the European Conference on Clinical Microbiology and Infectious Diseases (ECCMID), consultant clinical microbiologist and RIHS scientist Jakko van Ingen received the Young Investigator Award for his groundbreaking work on nontuberculous mycobacterial disease. Jakko has performed landmark studies which showed that pathogenicity of nontuberculous mycobacteria differs strongly by species, that current antibiotic treatment regimens can be optimized by better use of susceptibility testing and that several new and repurposed antibiotics can improve treatment outcomes in nontuberculous mycobacterial disease. For this work, captured in 170 papers in peer-reviewed journals and 10 book chapters, he received this prestigious award. 

Jakko van Ingen is member of theme Infectious diseases and global health.

Related news items


NIH grant for follow-up research on tuberculous meningitis

10 February 2022

Met subsidie van het Amerikaanse NIH gaat With a grant from the U.S. NIH, Reinout van Crevel will continue to unravel the disease process of tuberculous meningitis.

read more

Chronic malaria infections produce more and more infectious gametocytes

28 April 2021 In a recent article in Nature Communications, researchers from the department of Medical Microbiology uncovered intriguing dynamics in the production of the transmission stages of malaria parasites, gametocytes. read more

Rob Aarnoutse is appointed as professor in Translation pharmacology of antimicrobial agents in particular drugs for tuberculosis

25 January 2021

Hospital pharmacist and clinical pharmacologist Rob Aarnoutse is appointed as professor in ‘Translation pharmacology of antimicrobial agents, in particular drugs for tuberculosis’ at Radboud University / Radboudumc, starting 16 November 2020.

read more

Invasive fungal infections in influenza and COVID-19

8 July 2020 The Aspergillus fungus is found in the lungs of many COVID patients. A parallel occurs with influenza patients, who often develop a serious fungal infection. Although such a serious fungal infection seems to occur less frequently in COVID-patients, alertness remains necessary, read more

Early symptoms in Radboudumc healthcare workers who were tested for SARS-CoV-2

12 May 2020 In Eurosurveillance RIHS researcher Alma Tostmann and colleagues from the Radboudumc COVID-19 Team describe that general symptoms like fever, headache, general malaise and muscle ache were associated with a positive SARS-CoV-2 test. Respiratory symptoms however, were not predictive for SARS-CoV-2. read more

Minocycline to treat pulmonary Mycobacterium avium complex disease

9 May 2019

In Journal of Antimicrobial Chemotherapy Mike Ruth, Jakko van Ingen and colleagues showed that minocycline may be useful to treat pulmonary diseases caused by Mycobacterium avium complex bacteria. This is important as few drugs are active against this disease and treatment outcomes are very poor.

read more